Abstract
Aim: Short-time models (STM) to study the cardiotoxicity (acute or chronic) of doxorubicin in rats are of interest to assess protective interventions and pathways. STM promotes more ethical animal treatment with less stress, and at a lower cost compared to established longtime models (LTM). We wanted to investigate if a STM of 9 days yields the same information regarding cardiotoxicity as a LTM of 9 weeks.
Methods: Male Wistar rats received identical drug administration protocols in STM and LTM.
The two intervention groups (n = 6) received intraperitoneal (i.p.) injections of 2mg/kg doxorubicin every day on 5 consecutive days, with a total cumulative dose of 10mg/kg. The two control groups (n = 6), received an equivalent volume of saline injected every day on 5 consecutive days. Hearts from STM and LTM were excised and Langendorff-perfused after 9 days or 9 weeks, respectively, after the first drug injection. Cardiotoxicity was assessed in paced Langendorff hearts by release of hydrogenperoxide (H 2 O 2 ) and troponin T (TnT) in effluent, by myocardial accumulation of doxorubicin and its metabolite doxorubicinol, and by physiological parameters recorded during pressure, or volume regulated perfusion.
Results: In STM, hearts exposed to doxorubicin demonstrated a 15% reduction in left ventricular developed pressure (LVDP) irrespective of flow mode, and a 13% increase in aortic pressure (AoP), during volume regulated perfusion, an index of coronary resistance, compared to controls. Left ventricular end-diastolic pressure (LVEDP) was increased 72% during pressure regulated perfusion and 100% during volume regulated perfusion in STM. In LTM, hearts exposed to doxorubicin demonstrated a 40% reduction in LVDP during pressure regulated perfusion and a 20% reduction during volume regulated perfusion. LVEDP was 70% higher in doxorubicin treated hearts during pressure regulated perfusion and 80% higher during volume regulated perfusion. In addition, aortic pressure was increased 30% during volume regulated perfusion. In both STM and LTM, hearts exposed to doxorubicin
Introduction
The anthracycline doxorubicin is one of the most frequently prescribed anticancer drugs because of its activity in solid tumours as well as haematological malignancies. However, its pronounced cardiotoxicity limits long term use and prevents effective anticancer therapy. (1) A common approach to evaluating cardiac function is monitoring left ventricular ejection fraction. A weakness in this method is that cardiac damage is usually detected only when a functional impairment has already occurred, which leaves little room for early, preventive strategies.(2) Therefore, measurement of cardiospecific biomarkers can be a valid diagnostic tool for early identification, assessment, and monitoring of cardiotoxicity. Previous cardiotoxicity models include long term exposure to doxorubicin for [5] [6] [7] [8] [9] [10] [11] [12] weeks.(5-7) LTMs are time consuming, and represent long-time stress for the animals, and high mortality rates have been reported. (8, 9 ) Therefore, it is of interest to develop and test short-time models (STM) when studying cardiotoxicity of anthracyclines. A combination of in vivo and ex vivo animal models has the advantage that it includes relevant pharmacokinetic phases after administration of drugs in vivo. In addition, such a model allows controlled evaluation of relevant end points (cardiotoxicity) ex vivo, without interference of systemic effects. In this methodological study in rats we wanted to investigate if a STM model of 9 days is comparable to a LTM of 9 weeks to study relevant indices of cardiotoxicity of doxorubicin in hearts. Both models involved repetitive intraperitoneal injections of doxorubicin or saline in vivo, prior to evaluation of cardiotoxicity in ex vivo isolated Langendorff hearts. Previously described STMs have not studied the generation of free radicals and release of TnT, however, they have addressed physiological parameters describing reduction of cardiac function, and accumulation of doxorubicin in the myocard. (10, 11) Our STM model includes these important biomarkers, supplemented by measurement of doxorubicinol, and as such, is of interest to study protective interventions. Furthermore, the model allows switching between pressure and volume regulated flow, and the latter adds measurement of the resistance in the coronary vasculature induced by drug treatment. 
Methods

Materials
Animals
Male Wistar rats (200 ± 2g) were purchased from Taconic (Ejby, Denmark). The animals were housed in grid-bottom metal wire cages in a room maintained at a 12 hour light/dark cycle at a temperature of 20-22ºC. They were acclimatised for 2 weeks, housed 3 per cage and allowed free access to food pellets (Pellets rodent, Special Diets Service, UK) and tap water until injection of doxorubicin or saline. The animals were separated in individual cages based on their respective treatments protocols.
Langendorff perfusion model
The perfusion medium was a modified, oxygenated (95% O 2 and 5% CO 2 by the pedal-withdrawal reflex. The heart was rapidly excised and immediately placed in cold (4ºC) KHBB to temporarily stop its beating and preserve it from ischemic injury prior to perfusion. The heart was mounted on a steel cannula placed in the aorta and perfused retrogradely in a Langendorff system with the use of thermostated (37ºC) Lauda reservoirs (Lauda-Königshofen, Germany), perfusion lines, and heart chamber. first derivatives maximum (dp/dt max ) and minimum (dp/dt min ) were continuously displayed and recorded. Pacing (300 beats per minute by electric stimulation of 5V amplitude of 3ms duration) was obtained by placing one electrode on the right auricle and one on the steel cannula. Coronary flow rate was measured by timed collection of the coronary perfusate that dripped from the heart. At the end of the perfusion protocol hearts were removed from the Langendorff system and myocardial tissue from the left ventricle was dissected free and immediately frozen in liquid helium and stored at -80ºC until analysis of doxorubicin and doxorubicinol, within 14 days of termination of the Langendorff protocol. Effluent samples of 1mL were collected in 1.5mL polypropylene Eppendorf micro test tubes (Eppendorf Vertrieb, Wesseling-Berzdorf, Germany) from each heart, at the end of the perfusion protocol, and stored at 0ºC, until analysis for TnT within 4 days of termination of the Langendorff protocol.
Effluent samples of 1mL were collected in Eppendorf tubes from each heart, at the end of the perfusion protocol, and immediately analysed for H 2 O 2 , the samples were placed in a thermostated (37ºC) Eppendorf rack heated by a Lauda reservoir (Lauda-Königshofen, Germany). All experiments and analysis were carried out between 7am and 7pm.
Experimental groups, drug treatments and Langendorff protocols (Figure I)
Two protocols were tested: STM and LTM. Each protocol had an intervention group demarcated dox (doxorubicin) and a control group demarcated sal (saline).
The intervention groups STMdox (n = 6) and LTMdox (n = 6) received an i.p. injection of 2mg/kg doxorubicin every day on 5 consecutive days up to a total cumulative dose of 10mg/kg doxorubicin. 
Effluent content of TnT
TnT in cardiac effluent was measured using an Elecsys 2010 immunoassay analyzer (Roche Diagnostics Norway AS, Oslo, Norway), based on the sandwich principle. Total duration of assay: 9 minutes. 1st incubation: 50µL of sample, a biotinylated monoclonal cardiac TnTspecific antibody, and a monoclonal cardiac TnT-specific antibody labeled with a ruthenium complex (Tris(2,2-bipyridyl)ruthenium(II)-complex (Ru(bpy) )) reacted to form a sandwich complex. 2nd incubation: After addition of streptavidin-coated microparticles, the complex became bound to the solid phase via interaction of biotin and streptavidin. The reaction mixture was aspirated into the measuring cell where the microparticles were magnetically captured onto the surface of the electrode. Unbound substances were then removed with ProCell. Application of a voltage to the electrode then induced chemiluminescent emission which was measured by a photomultiplier. Results were determined via a calibration curve which was instrument-specifically generated by 2-point calibration and a master curve (5-point calibration) provided via the reagent barcode. Detection limit was 5.0ng/L Effluent content of H 2 O 2 H 2 O 2 in cardiac effluent was measured using an Apollo 4000 electrochemical detection system (World Precision Instruments, Sarasota, Florida, USA). The electrode was calibrated using 9 serial dilutions of H 2 O 2 in phosphate buffered saline with added aniline. The current recorded from the effluent was then calculated as µM H 2 O 2 . Samples were kept at 37°C during measurement. The electrode was allowed 3 minutes of stabilisation and 1 minute of recording.
Statistics
All results are reported as mean values ± standard deviation (SD) in tables. Groups were compared with regards to parameters with a student t-test. Only groups within similar protocols (STMdox with STMsal, and LTMdox with LTMsal) were compared. Differences between models were only described. SPSS for Windows version 17.0 was used, and p < 0.05 was considered statistically significant. during pressure regulated perfusion and 100% during volume regulated perfusion in STM. In LTM, hearts exposed to doxorubicin demonstrated a 40% reduction in LVDP during pressure regulated perfusion, and a 20% reduction during volume regulated perfusion. LVEDP was 70% higher in doxorubicin treated hearts during pressure regulated perfusion and 80% higher during volume regulated perfusion. In addition, aortic pressure was increased 30% during volume regulated perfusion. In both STM and LTM, hearts exposed to doxorubicin demonstrated a higher H 2 O 2 and TnT release, compared to respective controls. dp/dt max was lower and dp/dt min higher in STMdox and LTMdox compared to their respective controls, irrespective of perfusion mode. Coronary flow was decreased during pressure regulated perfusion, in the doxorubicin treated groups in both models, compared to controls. All physiological results are presented in Table I and II and biochemical and pharmacological   results in Table III and IV.
Discussion
Our study shows that a 9 day STM is sufficient time to demonstrate relevant indices of cardiotoxicity of doxorubicin in isolated Langendorff-perfused rat hearts, irrespective of flow mode. Our model allows parallel assessment of ROS and TnT release, myocardial content of anthracyclines and measurement of cardiac function. Biochemical differences are more pronounced in STM, while contractile differences are more pronounced in LTM. The latter reflects the accumulated myocardial contractile damage associated with doxorubicin in the tissue. However, STM represents a preferred model for preliminary preclinical studies of protective interventions with less stress for the animals, and at a lower cost. Interestingly, an increase of LVEDP between 70-100% was apparent already in our 9 day model and was still present after 9 weeks. However, the increase in coronary vascular resistance was doubled in the same period from 13-30%. Thus, long time effects of doxorubicin in the heart, affect both cardiomyocytes and the coronary arteries.
HPLC-MS/MS measurements of doxorubicin and its
Finally, use of pacing gave us the opportunity to study contractile indices without interference of arrhythmias associated with anthracyclines.(21) Thus, our STM seems robust and reproducible, and it should be possible to add new indices of cardiotoxicity into this model in future studies.
Limitations
The present STM is suitable for preclinical evaluation of new protective interventions to reduce anthracycline cardiotoxicity. However, protection in compressed doxorubicin regimens is not necessarily equiprotective when tested in a more clinically relevant chronic regimens. Such studies should be reserved for interventions proven effective and safe in STM.
Furthermore, the model allows the possibility to elucidate important pathways associated with cardioprotective principles.
Repeated i.p. injections could give development of scar tissue and thickened skin with reduced and unpredictable absorption of drugs. Furthermore, doxorubicin could give local tissue damage and inflammation. We were careful to alternate injection sites, using correct injection techniques including a suitable needle to reduce this problem. The compartmental distribution of doxorubicin in the myocardium or within cardiomyocytes is not known due to the fact that heart tissue was minced and homogenized. Precise cellular and subcellular distribution of the anthracycline is of relevance to understand mechanisms of cardiotoxicity.
Assessment of effect on cardiomyopathy is important in studies of anthracyclines. In our study, the condition of the heart at the two time points would be of interest. However, our model did not allow for cardiac pathology due to the tissue being used to detect doxorubicin and doxorubicinol.
We used cardiac pacing, which excludes the possibility of evaluating heart rate and electrocardiograms. This would have been valuable and interesting information considering the well-known association between arrhythmias and anthracyclines. However, assessment of cardiac function (recording of left ventricular developed pressure (LVDP) and secondarily derived contractility indices) was of particular importance in this study, and pacing was used to obtain optimal recordings not influenced by arrhythmias.
An experimental STM with a combination of in vivo doxorubicin administration and subsequent ex vivo evaluation of cardiotoxicity in the rat must make some compromises in comparison to the clinical administration of the drug. The development of cardiotoxicity in animal models with weekly injections is previously described in the literature. (17) Repetitive low doses are preferred compared to a single high dose in the rat, and every-other-day administration has been proposed. (22) In our STM we used daily i.p. injections to reduce duration of the experiments.
Non-invasive transthoracic echocardiography is suitable for studying development and course of anthracyclines cardiomyopathy, and development of heart failure in animal models.(23) Our global isovolumetric STM cannot reflect in vivo heart function, and reduction of contractile indices represents only indirect measures of heart failure. However, our STM is ideal to study contractile function in parallel with release of relevant biochemical parameters in real time specific to the heart. Release of biomarkers in blood associated with in vivo models could be subject to several systemic effects and be less specific to the organ of interest.
Our STM does not allow measurement of intracellular production and compartmental distribution and release of H 2 O 2 . Thus, release in effluate represents a sum of venous drain (majority) and exudate from the surface of the heart (minority) from the organ. After nine weeks, pathological changes in the heart could allow for a different distribution and release of H 2 O 2 . However, release is specific to the organ compared to in vivo models where development of heart failure would affect potential release from other organs.
Conclusion
STM is comparable to LTM to study relevant indices of cardiotoxicity of doxorubicin in rat hearts. Thus, STM could be a preferred model for further studies of protective interventions.
STM is a better alternative than previously described LTMs, because it submits the animals to less stress and discomfort. In addition a STM is less time consuming, more cost effective and more in accordance with the idea of refinement for use of laboratory animals. This study shows that our STM is a promising alternative for future preclinical studies of cardiotoxic mechanisms of doxorubicin and doxorubicinol, and for studies of protective interventions. Heart rate (beats per minute) 300 ± 0 300 ± 0 300 ± 0 300 ± 0 dp/dt max (mmHg/s) 3490. Coronary flow (ml/min) 8.1 ± 0.5 * 11.1 ± 0.6 12.5 ± 0 12.5 ± 0 
